Skip to content
Screener

Lantheus Holdings LNTH PYLARIFY — Revenue

Other product segments

Oncology
$240.37M—
Cardiology
$88.28M—
Definity
$88.28M+5.2%
Neuraceq
$39.62M—
Neurology
$39.62M—
Strategic Partnerships And Other
$19.92M+71.9%
Licenseand Royalty Revenues
$11.25M+222%
SPECT Business
$0—

Similar metrics at other companies

HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%
EAT
EATFranchise revenues — Revenue
$14.7M+21.5%
Cinemark Holdings logo
CNKOther Revenues — Revenue
$113.1M+18.2%

Other financials

Income statement

See full
Revenue$388.2M+2.7%
Gross profit$241.9M+0.4%
Operating income$100.2M+13.9%
Net income$75.0M-4.7%
EPS (diluted)$1.11-0.9%

Balance sheet

See full
Cash & equivalents$595.0M-14.7%
Total debt$626.8M+1.5%
Total equity$1.3B+12.4%
Total assets$2.4B+14.1%

Cash flow

See full
Operating cash flow$92.2M+5.9%
CapEx$2.3M-70.7%
Free cash flow$89.9M+13.5%

Valuation

See full
Market cap$6.63B+84.6%
Enterprise value$6.66B+89.7%
P/E24.1×+11.4×
P/S4.3×+1.9×

Profitability

See full
Gross margin60.1%-3.6pp
Operating margin19.4%-9.4pp
Net margin17.7%-0.9pp
FCF margin24.9%-6.6pp

Returns & leverage

See full
Return on equity22.2%-3.6pp
Debt / equity0.5×-0.1×
Current ratio3.1×-1.2×

Where this comes from

Reported directly by Lantheus Holdings in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Lantheus Holdings’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 8:01 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336795
(in thousands)Three Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
PYLARIFY$240,366$250,642$481,290$508,296
Total oncology240,366250,642481,290508,296
Neuraceq39,616—75,055—
Total neurology39,616—75,055—
DEFINITY88,27983,939172,906163,150
Total cardiology88,27983,939172,906163,150
Strategic partnerships and other19,91911,59036,26222,337
SPECT—31,874—57,026

Item 1. Financial Statements

FAQ

What is Lantheus Holdings's PYLARIFY — revenue?
Lantheus Holdings (LNTH) reported PYLARIFY — revenue of $240.37M in Q2 2026.
How has Lantheus Holdings's PYLARIFY — revenue changed year-over-year?
Lantheus Holdings's PYLARIFY — revenue decreased by 4.1% year-over-year, from $250.64M to $240.37M.
What is the long-term trend for Lantheus Holdings's PYLARIFY — revenue?
Over 4 years (2021 to 2025), Lantheus Holdings's PYLARIFY — revenue has grown at a 118.5% compound annual growth rate (CAGR), from $43.41M to $989.12M.
What does PYLARIFY — revenue mean?
This metric represents the total gross revenue generated from the sale of a specific diagnostic product line, excluding any taxes collected from customers. It serves as a primary indicator of market adoption and commercial performance for the company's key therapeutic or diagnostic offerings. Tracking this revenue stream allows investors to evaluate the growth trajectory and demand for specific product portfolios within the broader healthcare segment.

Ask your AI about Lantheus Holdings's pylarify — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude